Developing drugs for developing countries.
Repository Usage Stats
Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.
Published Version (Please cite this version)
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
David Ridley has served as the Faculty Director of the Center for Health Sector Management (HSM) at Duke University's Fuqua School of Business for more than a decade. HSM students comprise nearly 20 percent of Duke MBA graduates each year.
David is an economist focused on incentives for innovation and quality, as well as pricing. He is dedicated to creating and studying tools that improve health.
David was the lead author of two papers that became law. He and his colleagues proposed the Food and Drug Administration's priority review voucher program which became law in 2007. They also proposed the Environmental Protection Agency's vector expedited review voucher program which became law in 2022.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.